Immunotherapy in prostate cancer: current state and future perspectives

Keyphrases

• Prostate Cancer 100%
• Cell-based 33%
• Radioimmunotherapy 33%
• Tumor Microenvironment 33%
• Dendritic Cells 33%
• Viral Vectors 33%
• Prostate Tumor 33%
• Antibody-mediated 33%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 33%
• Immune Checkpoint Inhibitors 33%
• Vector-based 33%
• Chimeric Antigen Receptor T-cell Therapy 33%
• Immunotherapy Agents 33%
• Cancer-immunity Cycle 33%
• Antibody-drug Conjugate 33%
• Cancer Microenvironment 33%
• Combinatorial Approach 33%
• Bispecific Antibody 33%

Medicine and Dentistry

• Immunotherapy 100%
• Prostate Cancer 100%
• Radioimmunotherapy 25%
• Prostate Tumor 25%
• Dendritic Cell Vaccine 25%
• Tumor Microenvironment 25%
• Immune Checkpoint Inhibitor 25%
• Tumor Immunity 25%
• Virus Vector 25%
• Chimeric Antigen Receptor T-Cell Immunotherapy 25%
• Antibody-Drug Conjugate 25%
• Bispecific Antibody 25%
• Messenger RNA 25%

Immunology and Microbiology

• Immunotherapy 100%
• Prostate 100%
• Dendritic Cell Vaccine 33%
• Immunity 33%
• Tumor Immunity 33%
• Viral Vector 33%
• Chimeric Antigen Receptor T-Cell Therapy 33%
• Antibody Drug Conjugate 33%
• Bispecific Antibody 33%
• Immunology 33%